RNA‑binding protein CELF2 inhibits breast cancer cell invasion and angiogenesis by downregulating NFATc1 Corrigendum in /10.3892/etm.2022.11170

Zhou,Limin; Xie,Xiju

doi:10.3892/etm.2021.10330

RNA‑binding protein CELF2 inhibits breast cancer cell invasion and angiogenesis by downregulating NFATc1

Corrigendum in: /10.3892/etm.2022.11170

Authors:
- Limin Zhou
- Xiju Xie
View Affiliations

Affiliations: Department of The Second Section Office of Breast Tumor, Jilin Cancer Hospital, Changchun, Jilin 130000, P.R. China, Department of Breast Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Published online on: June 23, 2021 https://doi.org/10.3892/etm.2021.10330
Article Number: 898
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer constitutes a major cause of morbidity and mortality among women in China and worldwide. The aim of the present study was to investigate whether CUGBP Elav‑like family member 2 (CELF2) could inhibit breast cancer cell invasion and angiogenesis by downregulating nuclear factor of activated T cells 1 (NFATc1) expression. The expression of CELF2 and NFATc1 in breast cancer cells and tissues was detected by reverse transcription‑quantitative PCR analysis. H&E staining was used to assess the number of microvessels in tumor tissue. The expression of proteins associated with invasion and angiogenesis and NFATc1 in tumor tissues and transfected cells was examined by western blotting. RNA pull‑down assay was used to verify the interaction between CELF2 and NFATc1. Cell proliferation, invasion and tube‑forming ability was analyzed using Cell Counting Kit‑8, Transwell and HUVEC tube formation assays, respectively. CELF2 expression was found to be decreased in breast cancer cells, whereas CELF2 overexpression suppressed the proliferation and invasion of breast cancer cells and inhibited tumor growth and angiogenesis. Furthermore, CELF2 overexpression decreased the expression of N‑cadherin (N‑cad), CD34 and NFATc1 in tumor tissues, whereas NEAFc1 overexpression increased the expression of N‑cad and NFATc1 in MCF cells transfected with OverExp‑CELF2. CELF2 was found to be inversely associated with NFATc1, and NFATc1 overexpression reversed the effects of CELF2 overexpression. In conclusion, the findings of the present study demonstrated that CELF2 may inhibit breast cancer cell invasion and angiogenesis by downregulating NFATc1.

View Figures

View References

1	Harbeck N and Gnant M: Breast cancer. Lancet. 389:1134–1150. 2017.PubMed/NCBI View Article : Google Scholar
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020.PubMed/NCBI View Article : Google Scholar
3	Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F, Jemal A, Yu X and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016.PubMed/NCBI View Article : Google Scholar
4	Irnaten M, Zhdanov A, Brennan D, Crotty T, Clark A, Papkovsky D and O'Brien C: Activation of the NFAT-calcium signaling pathway in human lamina cribrosa cells in glaucoma. Invest Ophthalmol Vis Sci. 59:831–842. 2018.PubMed/NCBI View Article : Google Scholar
5	Lu WC, Xie H, Tie XX, Wang R, Wu AH and Shan FP: NFAT-1 hyper-activation by methionine enkephalin (MENK) significantly induces cell apoptosis of rats C6 glioma in vivo and in vitro. Int Immunopharmacol. 56:1–8. 2018.PubMed/NCBI View Article : Google Scholar
6	He RL, Wu ZJ, Liu XR, Gui LX, Wang RX and Lin MJ: Calcineurin/NFAT signaling modulates pulmonary artery smooth muscle cell proliferation, migration and apoptosis in monocrotaline-induced pulmonary arterial hypertension rats. Cell Physiol Biochem. 49:172–189. 2018.PubMed/NCBI View Article : Google Scholar
7	Müller MR and Rao A: NFAT, immunity and cancer: A transcription factor comes of age. Nat Rev Immunol. 10:645–656. 2010.PubMed/NCBI View Article : Google Scholar
8	Ouyang Z, Guo X, Chen X, Liu B, Zhang Q, Yin Z, Zhai Z, Qu X, Liu X, Peng D, et al: Hypericin targets osteoclast and prevents breast cancer-induced bone metastasis via NFATc1 signaling pathway. Oncotarget. 9:1868–1884. 2018.PubMed/NCBI View Article : Google Scholar
9	Liu M, Wei L, Wang Y, Liu P, Liu X and Zhang M: Effects of NFATc1 on proliferation and apoptosis of breast cancer cells by regulating RhoA /ROCK signaling pathway. Mod Oncol. 28:562–568. 2020.
10	He Y and Ding M: Research progress on the interaction between RNA binding proteins and RNA-proteins. Sci Technol Innovation. 10–13. 2020.
11	Piqué L, Martinez de Paz A, Piñeyro D, Martínez-Cardús A, Castro de Moura M, Llinàs-Arias P, Setien F, Gomez-Miragaya J, Gonzalez-Suarez E, Sigurdsson S, et al: Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer. Oncogene. 38:7106–7112. 2019.PubMed/NCBI View Article : Google Scholar
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
13	Dou YQ, Kong P, Li CL, Sun HX, Li WW, Yu Y, Nie L, Zhao LL, Miao SB, Li XK, et al: Smooth muscle SIRT1 reprograms endothelial cells to suppress angiogenesis after ischemia. Theranostics. 10:1197–1212. 2020.PubMed/NCBI View Article : Google Scholar
14	Jemal A, Bray F, Center M, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011.PubMed/NCBI View Article : Google Scholar
15	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Rebelo M, Parkin D, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2014.PubMed/NCBI View Article : Google Scholar
16	Snietura M and Lange D: Current ASCO/CAP 2013 recommendations for testing for HER2 status in breast cancer. Pol J Pathol. 65 (Suppl 2):S32–S41. 2014.PubMed/NCBI(In Polish).
17	Naja F, Fadel RA, Alameddine M, Aridi Y, Zarif A, Hariri D, Mugharbel A, Khalil M, Nahleh Z and Tfayli A: Complementary and alternative medicine use and its association with quality of life among Lebanese breast cancer patients: A cross-sectional study. BMC Complement Altern Med. 15(444)2015.PubMed/NCBI View Article : Google Scholar
18	Węsierska-Gądek J and Mauritz M: Why (multi)targeting of cyclin-dependent kinases is a promising therapeutic option for hormone-positive breast cancer and beyond. Future Med Chem. 8:55–72. 2016.PubMed/NCBI View Article : Google Scholar
19	Li D, Bachinski LL and Roberts R: Genomic organization and isoform-specific tissue expression of human NAPOR (CUGBP2) as a candidate gene for familial arrhythmogenic right ventricular dysplasia. Genomics. 74:396–401. 2001.PubMed/NCBI View Article : Google Scholar
20	Ramalingam S, Ramamoorthy P, Subramaniam D and Anant S: Reduced expression of RNA binding protein CELF2, a putative tumor suppressor gene in colon cancer. Immunogastroenterology. 1:27–33. 2012.PubMed/NCBI View Article : Google Scholar
21	Wang J, Liu L, Sun Y, Xue Y, Qu J, Pan S, Li H, Qu H, Wang J and Zhang J: miR-615-3p promotes proliferation and migration and inhibits apoptosis through its potential target CELF2 in gastric cancer. Biomed Pharmacother. 101:406–413. 2018.PubMed/NCBI View Article : Google Scholar
22	Yeung YT, Fan S, Lu B, Yin S, Yang S, Nie W, Wang M, Zhou L, Li T, Li X, et al: CELF2 suppresses non-small cell lung carcinoma growth by inhibiting the PREX2-PTEN interaction. Carcinogenesis. 41:377–389. 2020.PubMed/NCBI View Article : Google Scholar
23	Xu W, Gu J, Ren Q, Shi Y, Xia Q and Wang J, Wang S, Wang Y and Wang J: NFATC1 promotes cell growth and tumorigenesis in ovarian cancer up-regulating c-Myc through ERK1/2/p38 MAPK signal pathway. Tumour Biol. 37:4493–4500. 2016.PubMed/NCBI View Article : Google Scholar
24	Wang L, Wang Z, Li J, Zhang W, Ren F and Yue W: NFATc1 activation promotes the invasion of U251 human glioblastoma multiforme cells through COX-2. Int J Mol Med. 35:1333–1340. 2015.PubMed/NCBI View Article : Google Scholar
25	Liu Y, Liang T, Qiu X, Ye X, Li Z, Tian B and Yan D: Down-regulation of Nfatc1 suppresses proliferation, migration, invasion, and warburg effect in prostate cancer cells. Med Sci Monit. 25:1572–1581. 2019.PubMed/NCBI View Article : Google Scholar
26	Li L, Duan Z, Yu J and Dang HX: NFATc1 regulates cell proliferation, migration, and invasion of ovarian cancer SKOV3 cells in vitro and in vivo. Oncol Rep. 36:918–928. 2016.PubMed/NCBI View Article : Google Scholar